Putting The CAR-T Before The Horse

Emily BurkeThe WEEKLY

THE STORY BEHIND CAR-T The hottest cancer therapy in the pipeline — chimeric antigen receptor therapy (CAR-T) — got a big boost last month when an FDA advisory panel unanimously recommended approval of the treatment for children and young adults with a severe form of leukemia who have run out of other options. Developed by Novartis (Basel, Switzerland), this elegant … Read More

The Top Tech Of 2016

Emily BurkeBiotech Basics, Cancer, Clinical Trials, Drug Targets, FDA, Mechanism of Action

CAR-T Primer The hottest cancer therapy in the pipeline — chimeric antigen receptor therapy (CAR-T) — continued to mature in 2016 with its first FDA approval for blood cancer patients set to arrive this year. What’s next in the world of CAR-T? A whole lot: Additional cancer and autoimmune disease indications in preclinical development. Added safety features. More affordable “off … Read More

Cancer Vaccines & Game Changers

Emily BurkeBiologics, Cancer, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Genomics, Mechanism of Action, Term of the Week

The Elusive Cancer Vaccine The promise of cancer vaccines have proven to be elusive. A new crop of biotechs are hoping to change that by taking advantage of the latest advances in genomics. Scientists are working overtime trying to develop cancer vaccines that train the immune system to recognize and fight an established tumor. In this WEEKLY, we’ll break down the science … Read More

On A Tumor’s Turf

Emily BurkeBiologics, Cancer, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Small Molecule Drugs, The WEEKLY

TACKLING THE SPACE AROUND SOLID TUMORS Covering the science behind T-cell-based immunotherapies has been the name of the game for our past couple of issues. CAR-T and TCR therapies show significant promise in early phase blood cancer clinical trials, but what about solid tumors? Previously mentioned Juno Therapeutics’ (Seattle, WA) Armored CAR technology has declared war on tumors, and as you will read … Read More

Et Tu, Immune System?

Emily BurkeBusiness of Biotech, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Easily Confused, The WEEKLY

Autoimmune Disorders: A Story Of Betrayal “Et tu, Brute?” The famous line spoken by Shakespeare’s Julius Caesar is synonymous with unexpected betrayal by a close friend. A once trusted member of the inner circle, Marcus Brutus joined the coup and turned on Caesar. The 23.5 million Americans suffering from autoimmune disorders also have a Brutus in their midst—their own immune … Read More

Dodging Another Ebola Outbreak

Emily BurkeBiotech Basics, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Ebola, Genetics, HIV, The WEEKLY

Ebola Finally Meets Its Match The headlining Ebola crisis of last summer devastated West Africa, marking the largest outbreak since the discovery of the disease in 1976. The glaring lack of a treatment or vaccine caused the virus to quickly spread within Guinea, Sierra Leone, and Nigeria. A small number of infected healthcare workers were able to receive an experimental antibody known as Zmapp … Read More

Packing A Punch With The Immune System

Emily BurkeBiologics, Biotech Basics, Drug Targets, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

THE INNER WORKINGS OF YOUR IMMUNE SYSTEM What do monoclonal antibodies, CAR-T therapy, and 3D vaccines all have in common? They are immunotherapies, or therapies that activate a patient’s own immune system to fight or prevent a disease. While immune system activation can help save a life, an overactive immune system can potentially attack the body it is charged with … Read More

The Rise Of Nanomedicine

Emily BurkeCancer, Clinical Trials, Cocktail Fodder, Diagnostics, Drug Development, Drug Targets, FDA, The WEEKLY

Biotech Teams Up with Nanotech Imagine swallowing a pill containing microscopic magnets. After these “magnetic nanoparticles” make their way to the stomach, they are absorbed into the bloodstream to uncover disease associated proteins and other molecules. Envision these tiny explorers relaying their findings to a band worn discretely on your wrist. The potential to identify disease early with nanoparticles, rather than later with more conventional technologies, is a game … Read More